Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452190 · ClinicalTrials.gov registry record · Phase 3
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A Phase 3 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 468
- Enrollment target
- 20
- Study locations
NCT02452190: Completed Phase 3 study of Asthma, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT02452190 is a Phase 3 study of Asthma that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 468 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02452190, a Phase 3 study of Asthma, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 468 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.
Primary Outcome
A CAE was defined as a clinically-judged deterioration in asthma control, as determined by the investigator and as evidenced by new or worsening asthma signs or symptoms based on the participant's history, asthma control diary, physical examination, and/or ambulatory or clinic visit assessment of lung function and that resulted in a medical intervention, including at least 1 of the following: 1) use of systemic corticosteroids (oral or injection) or at least a doubling from a stable maintenance
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Reslizumab
Study Locations (20)
California
- Teva Investigational Site 13215 - Bakersfield
- Teva Investigational Site 13181 - Canoga Park
- Teva Investigational Site 13254 - Fresno
- Teva Investigational Site 13216 - Huntington Beach
- Teva Investigational Site 13247 - Long Beach
- Teva Investigational Site 13205 - Napa
- Teva Investigational Site 13764 - San Jose
- Teva Investigational Site 13252 - Stockton
- Teva Investigational Site 13251 - Walnut Creek
Florida
- Teva Investigational Site 13196 - Aventura
- Teva Investigational Site 13256 - Fort Lauderdale
- Teva Investigational Site 13203 - Kissimmee
- Teva Investigational Site 13197 - Miami
- Teva Investigational Site 13220 - Miami
- Teva Investigational Site 13243 - Miami
Alabama
- Teva Investigational Site 13212 - Birmingham
Arizona
- Teva Investigational Site 13241 - Flagstaff
Arkansas
- Teva Investigational Site 13194 - Glendale
Colorado
- Teva Investigational Site 13229 - Denver
Connecticut
- Teva Investigational Site 13766 - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 3 |
What the finished NCT02452190 record still lists
NCT02452190 is an interventional study that assigns participants to a tested intervention. The registered 468 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02452190 names 20 study sites across 7 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02452190 about?
NCT02452190 is a clinical study titled "Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils". The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.
What is the current status of trial NCT02452190?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 468 participants. The study started on 2015-09-28. Estimated completion is 2018-01-31.
What conditions does trial NCT02452190 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02452190?
The interventions under investigation include: Placebo (DRUG), Reslizumab (DRUG).
Who is sponsoring clinical trial NCT02452190?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02452190 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02452190's enrollment target sits among peer trials
468 80th of 374 higher than 295 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- NCT05357170 · 468 participants
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI